AI Article Synopsis

  • Vascular calcification in chronic kidney disease (CKD) is linked to increased cardiovascular problems, and effective interventions to slow its progression are still unclear.
  • A systematic review of 77 clinical trials assessed various treatments for vascular calcification in people with CKD, focusing on their effectiveness compared to placebos or standard care, with a moderate risk of bias identified in the studies.
  • Some treatments, like magnesium and sodium thiosulfate, showed consistent benefits, while others, including vitamin D and certain antiresorptive agents, had mixed or inconclusive results, indicating the need for more research.

Article Abstract

Background: Vascular calcification is associated with cardiovascular morbidity and mortality in people with CKD. Evidence-based interventions that may attenuate its progression in CKD remain uncertain.

Methods: We conducted a systematic review of prospective clinical trials of interventions to attenuate vascular calcification in people with CKD, compared with placebo, another comparator, or standard of care. We included prospective clinical trials (randomized and nonrandomized) involving participants with stage 3-5D CKD or kidney transplant recipients; the outcome was vascular calcification measured using radiologic methods. Quality of evidence was determined by the Cochrane risk of bias assessment tool and the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) method.

Results: There were 77 trials (63 randomized) involving 6898 participants eligible for inclusion (median sample size, 50; median duration, 12 months); 58 involved participants on dialysis, 15 involved individuals with nondialysis CKD, and 4 involved kidney transplant recipients. Risk of bias was moderate over all. Trials involving magnesium and sodium thiosulfate consistently showed attenuation of vascular calcification. Trials involving intestinal phosphate binders, alterations in dialysate calcium concentration, vitamin K therapy, calcimimetics, and antiresorptive agents had conflicting or inconclusive outcomes. Trials involving vitamin D therapy and HMG-CoA reductase inhibitors did not demonstrate attenuation of vascular calcification. Mixed results were reported for single studies of exercise, vitamin E-coated or high-flux hemodialysis membranes, interdialytic sodium bicarbonate, SNF472, spironolactone, sotatercept, nicotinamide, and oral activated charcoal.

Conclusions: Currently, there are insufficient or conflicting data regarding interventions evaluated in clinical trials for mitigation of vascular calcification in people with CKD. Therapy involving magnesium or sodium thiosulfate appears most promising, but evaluable studies were small and of short duration.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063901PMC
http://dx.doi.org/10.1681/ASN.2021101327DOI Listing

Publication Analysis

Top Keywords

vascular calcification
28
clinical trials
16
interventions attenuate
12
people ckd
12
trials involving
12
attenuate vascular
8
systematic review
8
trials
8
prospective clinical
8
calcification people
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!